284 related articles for article (PubMed ID: 29231062)
21. Immunotherapeutic approaches in prostate cancer: combinations and clinical integration.
Slovin SF
Am Soc Clin Oncol Educ Book; 2015; ():e275-83. PubMed ID: 25993186
[TBL] [Abstract][Full Text] [Related]
22. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
23. Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy.
Gomella LG; Gelpi-Hammerschmidt F; Kundavram C
Can J Urol; 2014 Apr; 21(2 Supp 1):48-56. PubMed ID: 24775724
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer immunotherapy.
McNeel DG
Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
Singh BH; Gulley JL
Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer vaccines: current status and future potential.
Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
[TBL] [Abstract][Full Text] [Related]
27. Prostate cancer vaccines: current status.
Hwang LC; Fein S; Levitsky H; Nelson WG
Semin Oncol; 1999 Apr; 26(2):192-201. PubMed ID: 10597730
[TBL] [Abstract][Full Text] [Related]
28. Current status of immunological approaches for the treatment of prostate cancer.
Drake CG; Antonarakis ES
Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018
[TBL] [Abstract][Full Text] [Related]
29. Development of PROSTVAC immunotherapy in prostate cancer.
Singh P; Pal SK; Alex A; Agarwal N
Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
[TBL] [Abstract][Full Text] [Related]
30. A comprehensive review of immunotherapies in prostate cancer.
Maia MC; Hansen AR
Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
[TBL] [Abstract][Full Text] [Related]
31. Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer.
Gardner TA; Elzey BD; Hahn NM
Hum Vaccin Immunother; 2012 Apr; 8(4):534-9. PubMed ID: 22832254
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer: advances in immunotherapy.
Hurwitz AA; Yanover P; Markowitz M; Allison JP; Kwon ED
BioDrugs; 2003; 17(2):131-8. PubMed ID: 12641491
[TBL] [Abstract][Full Text] [Related]
33. Chemotherapy and immunotherapy combination in advanced prostate cancer.
Slovin S
Clin Adv Hematol Oncol; 2012 Feb; 10(2):90-100. PubMed ID: 22402350
[TBL] [Abstract][Full Text] [Related]
34. Advances in cancer vaccines for immunotherapy of prostate cancer.
Jin T; Zhou C; Zhao L; Dong X; Zhou F
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 48(1):148-156. PubMed ID: 36935188
[TBL] [Abstract][Full Text] [Related]
35. [Not Available].
Oudard S; Thibault C; Angelergues A; Tartour E; Timsit MO; Mejean A; Michel C; Vano Y
Bull Cancer; 2016 Nov; 103 Suppl 1():S144-S150. PubMed ID: 28057178
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm.
Garcia JA; Dreicer R
Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467
[TBL] [Abstract][Full Text] [Related]
37. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions.
Wei XX; Fong L; Small EJ
Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270
[TBL] [Abstract][Full Text] [Related]
38. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy in prostate cancer: review of the current evidence.
Fernández-García EM; Vera-Badillo FE; Perez-Valderrama B; Matos-Pita AS; Duran I
Clin Transl Oncol; 2015 May; 17(5):339-57. PubMed ID: 25480118
[TBL] [Abstract][Full Text] [Related]
40. A New Era of Immunotherapy in Prostate Cancer.
Pizzola C; Rizvi SM; Joshi M
Curr Mol Pharmacol; 2016; 9(3):217-225. PubMed ID: 26177645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
